328 related articles for article (PubMed ID: 28341561)
21. Airway smooth muscle dysfunction in Pompe (
Keeler AM; Liu D; Zieger M; Xiong L; Salemi J; Bellvé K; Byrne BJ; Fuller DD; ZhuGe R; ElMallah MK
Am J Physiol Lung Cell Mol Physiol; 2017 Jun; 312(6):L873-L881. PubMed ID: 28336814
[TBL] [Abstract][Full Text] [Related]
22. Remarkably low fibroblast acid α-glucosidase activity in three adults with Pompe disease.
Wens SC; Kroos MA; de Vries JM; Hoogeveen-Westerveld M; Wijgerde MG; van Doorn PA; van der Ploeg AT; Reuser AJ
Mol Genet Metab; 2012 Nov; 107(3):485-9. PubMed ID: 23000108
[TBL] [Abstract][Full Text] [Related]
23. A chaperone enhances blood α-glucosidase activity in Pompe disease patients treated with enzyme replacement therapy.
Parenti G; Fecarotta S; la Marca G; Rossi B; Ascione S; Donati MA; Morandi LO; Ravaglia S; Pichiecchio A; Ombrone D; Sacchini M; Pasanisi MB; De Filippi P; Danesino C; Della Casa R; Romano A; Mollica C; Rosa M; Agovino T; Nusco E; Porto C; Andria G
Mol Ther; 2014 Nov; 22(11):2004-12. PubMed ID: 25052852
[TBL] [Abstract][Full Text] [Related]
24. Reduction of Autophagic Accumulation in Pompe Disease Mouse Model Following Gene Therapy.
McCall AL; Stankov SG; Cowen G; Cloutier D; Zhang Z; Yang L; Clement N; Falk DJ; Byrne BJ
Curr Gene Ther; 2019; 19(3):197-207. PubMed ID: 31223086
[TBL] [Abstract][Full Text] [Related]
25. Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle.
Koeberl DD; Luo X; Sun B; McVie-Wylie A; Dai J; Li S; Banugaria SG; Chen YT; Bali DS
Mol Genet Metab; 2011 Jun; 103(2):107-12. PubMed ID: 21397538
[TBL] [Abstract][Full Text] [Related]
26. Akt inactivation induces endoplasmic reticulum stress-independent autophagy in fibroblasts from patients with Pompe disease.
Nishiyama Y; Shimada Y; Yokoi T; Kobayashi H; Higuchi T; Eto Y; Ida H; Ohashi T
Mol Genet Metab; 2012 Nov; 107(3):490-5. PubMed ID: 23041259
[TBL] [Abstract][Full Text] [Related]
27. Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial.
Strothotte S; Strigl-Pill N; Grunert B; Kornblum C; Eger K; Wessig C; Deschauer M; Breunig F; Glocker FX; Vielhaber S; Brejova A; Hilz M; Reiners K; Müller-Felber W; Mengel E; Spranger M; Schoser B
J Neurol; 2010 Jan; 257(1):91-7. PubMed ID: 19649685
[TBL] [Abstract][Full Text] [Related]
28. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk.
Van den Hout JM; Kamphoven JH; Winkel LP; Arts WF; De Klerk JB; Loonen MC; Vulto AG; Cromme-Dijkhuis A; Weisglas-Kuperus N; Hop W; Van Hirtum H; Van Diggelen OP; Boer M; Kroos MA; Van Doorn PA; Van der Voort E; Sibbles B; Van Corven EJ; Brakenhoff JP; Van Hove J; Smeitink JA; de Jong G; Reuser AJ; Van der Ploeg AT
Pediatrics; 2004 May; 113(5):e448-57. PubMed ID: 15121988
[TBL] [Abstract][Full Text] [Related]
29. The pharmacological chaperone 1-deoxynojirimycin increases the activity and lysosomal trafficking of multiple mutant forms of acid alpha-glucosidase.
Flanagan JJ; Rossi B; Tang K; Wu X; Mascioli K; Donaudy F; Tuzzi MR; Fontana F; Cubellis MV; Porto C; Benjamin E; Lockhart DJ; Valenzano KJ; Andria G; Parenti G; Do HV
Hum Mutat; 2009 Dec; 30(12):1683-92. PubMed ID: 19862843
[TBL] [Abstract][Full Text] [Related]
30. Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa.
van der Ploeg AT; Barohn R; Carlson L; Charrow J; Clemens PR; Hopkin RJ; Kishnani PS; Laforêt P; Morgan C; Nations S; Pestronk A; Plotkin H; Rosenbloom BE; Sims KB; Tsao E
Mol Genet Metab; 2012 Nov; 107(3):456-61. PubMed ID: 23031366
[TBL] [Abstract][Full Text] [Related]
31. Response to Comments on "Increasing Enzyme Mannose-6-Phosphate Levels but Not Miglustat Coadministration Enhances the Efficacy of Enzyme Replacement Therapy in Pompe Mice".
George K; Anding A
J Pharmacol Exp Ther; 2024 May; 389(3):313-314. PubMed ID: 38772716
[TBL] [Abstract][Full Text] [Related]
32. Oral delivery of Acid Alpha Glucosidase epitopes expressed in plant chloroplasts suppresses antibody formation in treatment of Pompe mice.
Su J; Sherman A; Doerfler PA; Byrne BJ; Herzog RW; Daniell H
Plant Biotechnol J; 2015 Oct; 13(8):1023-32. PubMed ID: 26053072
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of glycogen biosynthesis via mTORC1 suppression as an adjunct therapy for Pompe disease.
Ashe KM; Taylor KM; Chu Q; Meyers E; Ellis A; Jingozyan V; Klinger K; Finn PF; Cooper CG; Chuang WL; Marshall J; McPherson JM; Mattaliano RJ; Cheng SH; Scheule RK; Moreland RJ
Mol Genet Metab; 2010 Aug; 100(4):309-15. PubMed ID: 20554235
[TBL] [Abstract][Full Text] [Related]
34. Avalglucosidase alfa: First Approval.
Dhillon S
Drugs; 2021 Oct; 81(15):1803-1809. PubMed ID: 34591286
[TBL] [Abstract][Full Text] [Related]
35. Autophagy in skeletal muscle: implications for Pompe disease.
Shea L; Raben N
Int J Clin Pharmacol Ther; 2009; 47 Suppl 1(Suppl 1):S42-7. PubMed ID: 20040311
[TBL] [Abstract][Full Text] [Related]
36. The emerging phenotype of late-onset Pompe disease: A systematic literature review.
Chan J; Desai AK; Kazi ZB; Corey K; Austin S; Hobson-Webb LD; Case LE; Jones HN; Kishnani PS
Mol Genet Metab; 2017 Mar; 120(3):163-172. PubMed ID: 28185884
[TBL] [Abstract][Full Text] [Related]
37. Enzyme replacement therapy in the mouse model of Pompe disease.
Raben N; Danon M; Gilbert AL; Dwivedi S; Collins B; Thurberg BL; Mattaliano RJ; Nagaraju K; Plotz PH
Mol Genet Metab; 2003; 80(1-2):159-69. PubMed ID: 14567965
[TBL] [Abstract][Full Text] [Related]
38. Teaching tolerance: New approaches to enzyme replacement therapy for Pompe disease.
Cousens LP; Mingozzi F; van der Marel S; Su Y; Garman R; Ferreira V; Martin W; Scott DW; De Groot AS
Hum Vaccin Immunother; 2012 Oct; 8(10):1459-64. PubMed ID: 23095864
[TBL] [Abstract][Full Text] [Related]
39. Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers.
Raben N; Fukuda T; Gilbert AL; de Jong D; Thurberg BL; Mattaliano RJ; Meikle P; Hopwood JJ; Nagashima K; Nagaraju K; Plotz PH
Mol Ther; 2005 Jan; 11(1):48-56. PubMed ID: 15585405
[TBL] [Abstract][Full Text] [Related]
40. New therapeutic approaches for Pompe disease: enzyme replacement therapy and beyond.
Kishnani PS; Beckemeyer AA
Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():114-24. PubMed ID: 25345093
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
